Company Vital Therapies Inc Nasdaq
Equities
US92847R1041
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel Vitt
CEO | Chief Executive Officer | 55 | 16-12-31 |
Glenn Whaley
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Hella Kohlhof
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-12-31 |
Andreas Muehler
CTO | Chief Tech/Sci/R&D Officer | 60 | 16-07-31 |
Jessica Breu
IRC | Investor Relations Contact | - | - |
Patrick Walsh
PRN | Corporate Officer/Principal | 41 | 21-10-13 |
Inderpal Singh
LAW | General Counsel | 58 | 21-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Barclay Phillips
BRD | Director/Board Member | 61 | 19-11-18 |
Tamar Howson
BRD | Director/Board Member | 75 | 19-10-10 |
Jörg Neermann
BRD | Director/Board Member | 57 | 19-03-31 |
Daniel Vitt
CEO | Chief Executive Officer | 55 | 16-12-31 |
Duane Nash
CHM | Chairman | 53 | 18-12-31 |
Richard Rudick
BRD | Director/Board Member | 73 | 23-04-25 |
Monika Tornsen
BRD | Director/Board Member | 45 | 22-07-04 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 90,079,016 | 82,989,362 ( 92.13 %) | 0 | 92.13 % |
Company contact information
Immunic, Inc.
1200 Avenue of the Americas Suite 200
10036, New York
+
http://www.immunic-therapeutics.comSector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.11% | 22.2B | |
-16.53% | 21.23B | |
-9.93% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |